Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement

2007/06/14 by Sven Brandau, H. Suttmann, Henrik Suttmann · 3 citations
Medicine · #Bladder and Urothelial Cancer Treatments #Urinary Tract Infections Management #Urinary and Genital Oncology Studies

paper · doi:10.1016/j.biopha.2007.05.004

openalex publication_date 2007/06/14 · crossref created 2007/06/14 · crossref issued 2007/07/01 · crossref published 2007/07/01 · crossref published-print 2007/07/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/10 · crossref indexed 2026/02/02 · openalex updated_date 2026/07/23

Citations

• Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
• CANCER AND TUBERCULOSIS*

Cited by

• Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy
• TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis
• BCG vaccine [wikipedia]